Participated · Series B · Jun 2024

Integrum operates in the medical technology sector, developing healthcare solutions (specific products are not detailed in the article). The company is currently focused on shoring up liquidity ahead of an upcoming rights issue. To bridge its immediate working-capital needs, Integrum has arranged a short-term loan facility of up to SEK 7 million. Management considers the loan terms—3 % setup fee and 1 % fixed monthly interest—competitive given the firm’s financial position. The facility must be repaid by 31 December 2025, although the company intends to retire the debt once proceeds from the planned rights issue are received. This financing underscores Integrum’s proactive approach to capital management as it prepares for the next phase of funding.